ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis

Exclusion Criteria

• •Possible or confirmed diagnosis of Crohn's Disease or other forms of inflammatory bowel disorders
• •Ongoing or failed prior treatment for UC with methotrexate, azathioprine, 6-mercaptopurine, cyclosporine, tofacitinib, mycophenolate mofetil, sirolimus (rapamycin), thalidomide, tacrolimus (FK-506), or biologics (e.g., TNF-alpha-antagonists, anti-integrin therapies, or agents targeting IL-12 or IL-23, etc.)
• •Any immunosuppressive condition or treatment with immunosuppressive medications
• •History of prior surgical intervention in any region of the gastrointestinal tract (excluding minor surgery)
• •Prior diagnosis of any cardiovascular, renal, hepatic, endocrine, infectious, hematological, oncologic, neuro-psychiatric or immune-mediated disorder, which in the opinion of the Principal Investigator might impact the subject's safety or compliance, or the interpretation of results
• •Treatment with any other investigational drugs ≤12 weeks prior to baseline visit
• •The participant has a condition or is in a situation which, in the Principal Investigator's opinion, may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study